Intensity modulated radiotherapy in combination with endocrinotherapy in the treatment of middle and advanced Prostatic Cancer: Treatment of middle and advanced Prostatic Cancer

Objective: To evaluate the clinical efficacy of intensity modulated radiation therapy and endocrinotherapy for middle and advanced prostate cancer.

Methods: Total 104 elderly patients with middle and advanced prostate cancer who were admitted to our hospital from November 2014 to August 2015 were selected using random number table method. They were divided into intensity-modulated radiotherapy combined with endocrinotherapy group (observation group) and conventional radiotherapy combined with endocrinotherapy group (control group), 52 each. The serum levels of prostate specific antigen (PSA) and free prostate antigen (f PSA) were measured three months after treatment. The short-term efficacy and toxic and side effects of the patients were observed, and the survival rate was recorded through three-year follow up.

Results: The clinical effective rate of the observation group was 92.68%, and that of the control group was 70.73%; there was a significant difference between the two groups (P<0.05). The serum PSA and f PSA levels of the two groups were similar before treatment, but there was no significant difference (P>0.05). The serum PSA and f PSA levels after treatment were significantly lower than before treatment. The incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05). The one-year and three-year survival rates of the two groups were significantly different (90.0 vs. 80.0%, 60.0 vs. 43.3%, P>0.05).

Conclusion: Intensity modulated radiotherapy combined with endocrinotherapy was safe and well tolerated in the treatment of middle and advanced prostate cancer. It can improve the short-term efficacy and effectively reduce the serum oncological index concentration of patients. It can be promoted in clinics.